Company profile
CDR-Life AG
Wagistrasse 27
8952 Schlieren-Zurich
Switzerland
8952 Schlieren-Zurich
Switzerland
Immunotherapies for solid tumors
Biotech
CDR-Life is developing highly specific antibody therapeutics to target intracellular proteins presented on the major histocompatibility complex (MHC). Our versatile MHC-targeted antibody platform increases access to a vast array of antigens that were not previously addressable, to develop a pipeline of first in class therapeutics across a broad range of solid tumors. With a team of proven drug development experts and backed by leading cross-Atlantic investors, we are working to redirect and activate the patient’s own immune system to eliminate their tumors.